China
Africa
Explore chapters and articles related to this topic
Meeting personal needs: hydration and nutrition
Published in Nicola Neale, Joanne Sale, Developing Practical Nursing Skills, 2022
You may have thought of the following: Intravenously (IV): into the vein.Subcutaneous (SC) (hypodermoclysis): into subcutaneous tissue. This route is a valuable alternative method of fluid delivery to the traditional intravenous route, particularly used for older people. It has many advantages over parenteral fluid administration, including ease of administration and fewer systemic side effects.Intra-osseous (IO): directly into the bone marrow of the antero-medial aspect of the tibia (most popular), femur, iliac crest or humerus.
Support for Hydration at End of Life
Published in Victor R. Preedy, Handbook of Nutrition and Diet in Palliative Care, 2019
The use and safety of hypodermoclysis have been well documented and reported, and there have been studies in palliative care populations demonstrating ease of administration with minimal side effects. The application of hypodermoclysis is simple and is associated with minimal discomfort. A subcutaneous needle is inserted and attached to a fluid line that can be run using gravity or an infusion pump. Relatively little training for insertion and surveillance is required, and families can be trained to use this option at home with minimal burden, equipment or technical support (Vidal et al. 2016).
Nutrition and Hydration
Published in Margaret O’Connor, Sanchia Aranda, Susie Wilkinson, Palliative Care Nursing, 2018
In some situations, for example in bowel obstruction for which surgery is not considered appropriate, the person can have fluids provided subcutaneously. This is referred to as ‘hypodermoclysis’, and it can be of benefit in the home setting or in residential aged care, where a registered nurse might not be readily available 24 hours a day. Fluids can be administered in this way as a bolus, continuously, or during the night while the person is sleeping (at a rate of about 1 litre over an 8-hour period) (Jackson 2000). This means of hydration can be effective when other avenues are not available (Malone 1994; Steiner & Bruera 1998; Noble-Adams 1995; Worrobee & Brown 1997). This method of hydration can be readily and safely used in the home setting (with the support of a nurse), and there is no need for hospitalisation.
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Published in Expert Opinion on Drug Delivery, 2021
Stephen P. Knowles, Marie A. Printz, David W. Kang, Michael J. LaBarre, Renee P. Tannenbaum
In a post-marketing study of 16 elderly patients with primary or secondary immunodeficiencies, rHuPH20-facilitated SC 10% human blood-derived polyclonal immunoglobulin was well tolerated [49]. Six patients reported local adverse drug reactions: redness (n = 2), rash (n = 2), pain at the infusion site (n = 2), and feeling of a bloated abdomen (n = 1). Two patients reported systemic adverse drug reactions: a single night of sleeplessness (n = 1) and slight malaise on the day of the infusion (n = 1) [49]. In another study, 32 patients in a hospice setting received rHuPH20 to enhance hypodermoclysis with standard hydration fluids (n = 26) or to enhance SC infusion of nine medications (n = 6). Higher than expected serum lidocaine concentration was observed in 1 patient, but no other significant AEs were reported [87].
The duration of hyaluronidase and optimal timing of hyaluronic acid (HA) filler reinjection after hyaluronidase injection
Published in Journal of Cosmetic and Laser Therapy, 2018
H. J. Kim, S. B. Kwon, K. U. Whang, J. S. Lee, Y. L. Park, S. Y. Lee
Hyaluronidase was developed as a spreading agent to promote the permeation and diffusion in connective tissue through the hydrolysis of HA. These enzymes have been approved for 3 purposes: (1) as an adjuvant to increase the absorption and dispersion of other injected drugs; (2) to produce hypodermoclysis; and (3) as an adjunct in subcutaneous urography for improving reabsorption of radiopaque agents (10). The use of hyaluronidase for correction of HA filler skin augmentation is an off-label application of its Food and Drug Administration (FDA)-approved indications. Hyaluronidases can be employed for eliminating nodules or bumps, for treating an overcorrection by HA filler injection and/or excessive superficial infiltrations. The modalities of hyaluronidase injection depend on the localization and quantity of the previous HA filler injection. Generally, 15–30 units of hyaluronidase is recommended for nasal, perioral skin, 30 units for periorbital area, and 10–15 units for infraorbital area (5,11,12). For the lower eye lid, 1.5 units is sufficient for correction (13).